PharmiWeb.com - Global Pharma News & Resources

Marketing - Press Releases

Date Title Company
20-Feb-2020 Medigene AG: Medigene participates at upcoming conferences Medigene AG
19-Feb-2020 Pfizer’s Vyndaqel set to achieve blockbuster status in 2021 with new EU approval for expanded use in ATTR-CM Pfizer
19-Feb-2020 Driven by its successful debut, the Second Annual International HealthTech Innovation Days will take place in Paris on June 22nd & 23rd France Biotech
19-Feb-2020 Lundbeck increases its share capital by 11,497 shares (0.0058 % of outstanding shares) as a result of exercise of employee warrants Lundbeck
19-Feb-2020 Orgenesis announces collaboration with the John Hopkins University for the development and processing of cell and gene based clinical therapeutics Orgenesis
19-Feb-2020 Immutep reports positive TACTI-002 data Immutep
19-Feb-2020 European Commission Grants Marketing Authorisation for VYNDAQEL®  (tafamidis), the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pfizer
19-Feb-2020 SEARCHING FOR BIOMARKERS AND THERPEUTIC AGENTS AGAINST BREAST CANCER Karl Landsteiner University
18-Feb-2020 Director resignation - H.J. Mark Tompkins NMC HEALTH PLC
18-Feb-2020 Director resignation - Mr Abdulrahman Basaddiq NMC HEALTH PLC
18-Feb-2020 Director resignation - Hani Buttikhi NMC HEALTH PLC
18-Feb-2020 New company takes aim at treatments for multiple sclerosis Pheno Therapeutics
18-Feb-2020 DNX Biopharmaceuticals Announces Collaboration With Lung Cancer Initiative at Johnson & Johnson DNX Biopharmaceuticals, Inc
18-Feb-2020 Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine Sanofi
18-Feb-2020 New large chamber laboratory washers boast eco-friendly technology Miele GB
17-Feb-2020 Director resignation NMC Health plc
17-Feb-2020 ReNeuron Group plc - Positive Phase 2a stroke clinical data published ReNeuron Group plc
17-Feb-2020 Vifor Pharma acquires Priority Review Voucher Vifor Pharma Group
17-Feb-2020 Analysis of RNA sequences and modifications by mass spectrometry published in Nature Communications STORM Therapeutics Ltd
17-Feb-2020 Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease Takeda Pharmaceutical Company Limited